PMID: 9526179Apr 4, 1998Paper

A double-blind comparison of the efficacy and safely of paroxetine and imipramine in the treatment of depression with dementia

International Journal of Geriatric Psychiatry
C L KatonaJ Bray

Abstract

To compare the efficacy of paroxetine and imipramine prospectively in patients with coexisting depression and dementia. An 8-week, double-blind, parallel group trial comparing paroxetine 20-40 mg/day with imipramine 50-100 mg/day in 198 patients aged 60 years or over with a Montgomery-Asberg Depression Rating Scale (MADRS) score > or = 20 and a Folstein mini-mental state evaluation score of 17-23 points after a 3- to 7-day placebo run-in period. Both paroxetine and imipramine reduced the MADRS and the Clinical Global Impression (CGI) severity-of-illness and global improvement scores at weeks 2, 4, 8 and at endpoint, with no significant differences between treatment groups at any timepoint (MADRS, p > or = 0.368; cgi, p > or = 0.286). There was a statistically significant difference in favour of paroxetine at both the week 4 and week 8 timepoints (analysis of variance, p < or = 0.049) in the Cornell scale for depression in dementia: at endpoint there was no significant difference between treatments (p = 0.103). Treatment-emergent adverse experiences were reported by 51.5% (51/99) of patients treated with paroxetine and 50.5% (50/99) of patients treated with imipramine. Anticholinergic adverse experiences (paroxetine 6.1%; imipra...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Jun 1, 1992·International Clinical Psychopharmacology·I Hindmarch
Sep 1, 1991·The British Journal of Psychiatry : the Journal of Mental Science·G C DunbarR K Shrivastava
May 1, 1989·The American Journal of Psychiatry·R E Wragg, D V Jeste
Feb 1, 1988·Biological Psychiatry·G S AlexopoulosC A Shamoian
May 1, 1986·Annals of Neurology·W A RoccaB S Schoenberg
Dec 1, 1982·Archives of Gerontology and Geriatrics·C G GottfriesG Steen
Dec 1, 1993·Journal of Clinical Psychopharmacology·J L Claghorn, J P Feighner
Sep 1, 1995·Drugs & Aging·C A NaranjoK E Bremner
Oct 1, 1995·Journal of Geriatric Psychiatry and Neurology·L Teri, R G Logsdon

❮ Previous
Next ❯

Citations

Jan 13, 2001·Journal of Affective Disorders·G A Carlson
Jan 13, 2001·Journal of Affective Disorders·E B Weller, R A Weller
Dec 15, 2000·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C Katona
Oct 16, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Isaac
Jul 4, 2001·Clinical Cornerstone·D I Kaufer
Jul 20, 2005·Journal of Clinical Psychopharmacology·K Ranga Rama Krishnan
Mar 2, 2006·Drugs & Aging·Carlo CaltagironeUNKNOWN Italian Association of Psychogeriatrics
Sep 24, 2008·Drugs & Aging·Tarek K RajjiCharles F Reynolds
Apr 20, 2005·PharmacoEconomics·Daniel L Murman, Christopher C Colenda
May 25, 2002·CNS Drugs·Antona J WagstaffKaren L Goa
Feb 26, 2008·Aging & Mental Health·C L Williams, R M Tappen
Dec 14, 2002·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Michael BauerUNKNOWN World Federation of Societies Biological Psychiatry Task Force on Treatment Guidelines for Unipolar Depressive Disorders
Dec 12, 2001·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·B H MulsantC F Reynolds
Sep 6, 2002·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Alan F SchatzbergUNKNOWN Mirtazapine vs. Paroxetine Study Group
Aug 17, 2002·Biological Psychiatry·Constantine G Lyketsos, Jason Olin
Apr 2, 2002·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Jason T OlinBarry D Lebowitz
Mar 4, 2003·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Stephen J BartelsAnne C Voss
May 16, 2000·Journal of the American Geriatrics Society·B V Reifler
Jul 12, 2002·International Journal of Geriatric Psychiatry·Krista L LanctôtClaudio A Naranjo
May 7, 1999·Journal of Geriatric Psychiatry and Neurology·B S Meyers
Mar 29, 2003·Current Medical Research and Opinion·Ben Green
Sep 2, 2003·International Journal of Geriatric Psychiatry·Robert C BaldwinUNKNOWN Faculty of Old Age Psychiatry Working Group, Royal College of Psychiatrists
Nov 6, 2008·Expert Opinion on Drug Safety·David M MarksChi-Un Pae
Feb 26, 2010·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Yekta DowlatiKrista L Lanctôt
Jan 26, 2010·International Psychogeriatrics·Serge GauthierConstantine Lyketsos
Oct 16, 2019·Frontiers in Pharmacology·Tommaso CassanoSilvana Gaetani
Jun 23, 2001·CNS Drug Reviews·M BourinY Guillon
Dec 21, 2000·Current Psychiatry Reports·C Ballard, M Walker
Jul 14, 2000·Epidemiologia e psichiatria sociale·M Balestrieri
Nov 30, 2000·Current Treatment Options in Neurology·A S Schachter, K L Davis
Dec 21, 2000·Current Psychiatry Reports·R J Boland
Mar 15, 2002·Drugs·Antona J WagstaffKaren L Goa
Feb 7, 2003·International Journal of Geriatric Psychiatry·D P DevanandHarold A Sackeim
Feb 18, 2004·Internal Medicine·Shigenobu Nakamura
Jul 2, 2005·Journal of Psychiatric Practice·G S AlexopoulosR W Ross
Nov 6, 2007·International Journal of Geriatric Psychiatry·George S AlexopoulosChristopher F Murphy
Sep 7, 2016·International Journal of Geriatric Psychiatry·Nicolas FarinaSube Banerjee
Sep 1, 2018·The Cochrane Database of Systematic Reviews·Robert DudasTom Dening
Nov 26, 1999·The New England Journal of Medicine·R Mayeux, M Sano
Feb 23, 2000·Arquivos de neuro-psiquiatria·O P Almeida
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P J Goodnick, M Hernandez
Mar 14, 2003·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Dan G Blazer
Sep 15, 2005·Acta Clinica Belgica·M PetrovicL Van Bortel
Jan 10, 2003·The Cochrane Database of Systematic Reviews·Jatinder BainsTom Dening
Jun 21, 2006·Expert Review of Neurotherapeutics·Sergio E Starkstein, Romina Mizrahi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.